NRAS and lung carcinoma: The Downward group has reported several murine KRASG12C-driven lung cancer cell lines including an NRAS-deleted derivative of the LLC model as well as KPARG12C and KPB6G12C cells that exhibit varying degrees of in vivo sensitivity to KRASG12C inhibitors (28, 34, 44, 45).